Thus, after anti-EGFR drug-free intervals that allow for the clearance of resistant cancer cell clones, a rechallenge with EGFR inhibitors might represent an appealing therapeutic option in patients that benefit from prior anti-EGFR therapy [1,2,11]. Here, EGFR is linked to cancer.